A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NSGCT / nonseminomatous germ cell tumors

[Related PubMed/MEDLINE]
Total Number of Papers: 394
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NSGCT  (>> Co-occurring Abbreviation)
Long Form:   nonseminomatous germ cell tumors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Active surveillance in stage 1 disease: standard of care independent of risk factors? CS1
2020 Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. AS, RPLND
2020 Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors. BEP, LVI, RPLND
2020 Growing teratoma syndrome of mediastinal nonseminomatous germ cell tumor. GTS
2020 Robot-assisted laparoscopic retroperitoneal lymph node dissection: a minimally invasive surgical approach for testicular cancer. L-RPLND, O-RPLND, R-RPLND, RPLND
2020 Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors. nsRPLND, TGCT
2019 Cell-to-cell variation of chromosomal number in the adult testicular germ cell tumors: a comparison of chromosomal instability among histological components and its putative role in tumor progression. GCNIS, TGCTs
2019 Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries. EFS, GCTs, IGCCCG, LMIC, OS
10  2019 First - line, non - cryopreserved autologous stem cell transplant for poor - risk germ - cell tumors: Experience in a developing country. autoHSCT, HDC
11  2019 High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. BED, BM, HR, ICC, OS, RT
12  2019 Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. CI, CSM, CSS, HR, LNC, NCDB, OM, OS, PC-RPLND, SEER
13  2019 Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. PC-RPLND, RPLND
14  2019 Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes. IQR
15  2019 Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours. RA-RPLND, RASE-RPLND
16  2019 Solitary Bone Metastasis as the First Presentation of Germ Cell Testicular Cancer Treated with Internal Hemipelvectomy: A Case Report. ---
17  2019 Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. PC-RPLND
18  2019 Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. AS, RPLND
19  2018 A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer. CS, LRPLND, R-RPLND
20  2018 Brain angiometastasis from a non-seminomatous germ cell tumor: A case report. AV
21  2018 Choriocarcinoma Syndrome as an Initial Presentation of Testicular Cancer. beta-hCG, CS
22  2018 Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. APC, AT, CI, IPTW, OS
23  2018 Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. CI, GCT, RPLND
24  2018 Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients. AS, CS, DMC, EAU, SGCT, TGCT
25  2018 Impact of hospital case volume on testicular cancer outcomes and practice patterns. RPLND, TGCTs
26  2018 Lymph node imaging in testicular cancer. CT, MRI, PET
27  2018 Minimally Invasive Retroperitoneal Lymphadenectomy. CSI, RLA
28  2018 Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor. ---
29  2018 Outcomes of active surveillance of clinical stage I non-seminomatous germ cell tumors: sub-analysis of the multi-institutional nationwide case series of the Japanese Urological Association. RFS
30  2018 Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: Feasibility and outcomes of initial cases. RA-RPLND
31  2018 Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer. CSI, PC, PEB, RPLND, TGCT
32  2018 Pure Testicular Choriocarcinoma with Dermatological, Brain, and Gastrointestinal Metastases. ---
33  2018 Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. RPLND
34  2018 Sonographic classification of testicular tumors by tissue harmonic imaging: experience of 58 cases. LHT, SGCT, TPS
35  2018 Stereotactic ablative body radiotherapy (SABR) for inoperable, chemorefractory retroperitoneal lymph node relapse from non seminomatous germ cell tumour of testis: a case report. SABR
36  2018 Testicular non-seminomatous germ cell tumors (NSGCT) and brain metastases: About a rare location of the posterior fossa. ---
37  2017 A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. TGCT, TRIM44
38  2017 Andrological complications following retroperitoneal lymph node dissection for testicular cancer. ED, PC-RPLND, RE, RPLND
39  2017 Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. CI, cRR, CSI
40  2017 Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. ---
41  2017 Hepatic angiosarcomatous transformation of a mediastinal germinal cell tumor: A care case report. CT, MRI, PET
42  2017 Impact of Urologist Density and County Rurality on the Practice of Retroperitoneal Lymph Node Dissection and Cancer-Specific Death in Patients with Nonseminomatous Germ Cell Tumors. CSD, RPLND, SEER
43  2017 Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. CS, RPLND
44  2017 Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. PC-RPLND
45  2017 Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. CT, MRI
46  2017 Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. CSI, EC, LVI, RFS, RPLND
47  2017 Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Non-Seminomatous Germ Cell Tumour (NSGCT). Diabetic RetinaScreen
48  2017 Robot - assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. RPLND
49  2017 Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. CS, IQR, R-RPLND
50  2017 The Significance of Lymphovascular Invasion of the Spermatic Cord in the Absence of Cord Soft Tissue Invasion. LVI
51  2016 Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India. CR, CT, GCTs, PR
52  2016 Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. ADCs, FNA, IHC, NSCLC, PD CA, SCLCs, SqCC, TMA
53  2016 Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. EYST, EYT
54  2016 Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. ---
55  2016 Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience. IGCCCG, PC, RPLND, RRPLND
56  2016 Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes. RPLND
57  2016 Scrotal Involvement with Testicular Nonseminomatous Germ Cell Tumour. CT
58  2016 Surgical controversies in the management of post-chemotherapy nonretroperitoneal residual disease in metastatic nonseminomatous germ cell tumors. ---
59  2016 Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011). RPLND
60  2015 A 20-Year Epidemiological Review of Testis Cancer at a French Military Hospital. ---
61  2015 Clinical presentation features of testicular cancer in public hospitals in the Autonomous Community of Madrid, Spain. ---
62  2015 Extended cervico-thoracic metastasectomy for testicular non-seminomatous germ cell tumour masses through an inverse T and combined collar incision. ---
63  2015 Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy. BEP, CSI
64  2015 Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. CSS, FFS, IGCCC, RBM3
65  2015 Management of Stage I Nonseminomatous Germ Cell Tumors. CS
66  2015 Mediastinal germ cell tumour causing superior vena cava tumour thrombosis. BEP, FDG, PET-CT, SVC
67  2015 Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. EBL, LN, LOS, RA-RPLND, RMS
68  2015 Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. GCC, MDCT
69  2015 The value of testicular ultrasound in the prediction of the type and size of testicular tumors. SGCT, US
70  2015 [Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors. Laparoscopic management - limits and chances]. CS, LRPLND
71  2015 [Reduced morbidity in resection of residual tumors after chemotherapy for seminoma]. PC-RPLND
72  2014 A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. DFCI, PC-RPLND
73  2014 A prospective study of cognitive function in men with non-seminomatous germ cell tumors. HE, LE
74  2014 Anatomical retroperitoneoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors: initial operative experience. ARRPLND
75  2014 Disseminated ovarian Growing Teratoma Syndrome: a case -report highlighting surgical safety issues. GTS
76  2014 Erectile dysfunction in men treated for testicular cancer. DUS, ED, IIEF, PDE5i, RPLND, TC
77  2014 External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. RPLND
78  2014 Growing teratoma syndrome. GTS
79  2014 Management of the primary malignant mediastinal germ cell tumors: experience with 54 patients. PMMGCT
80  2014 Mixed germ cell testicular cancer with left ventricular metastasis presenting with embolic stroke and small bowel tumor seeding. GCTs
81  2014 Postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels. LRPLND
82  2014 Prediction of metastatic status in non-seminomatous testicular cancer. ---
83  2014 Primary nonseminomatous germ cell tumor in the posterior mediastinum. CT
84  2014 Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis. EL-RPLND, RPLND, TL-RPLND
85  2014 [Comprehensive treatment of stage-lllb testicular non-seminomatous germ cell tumor: a case report and review of the literature]. nsLRPLND
86  2013 Controversies in the management of stage 1 non-seminomatous germ cell tumors. CS1
87  2013 Is modified retroperitoneal lymph node dissection alive for clinical stage I non-seminomatous germ cell testicular tumor? CS, PS, RPLND
88  2013 Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. RPLND, TGCTs
89  2013 Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. RPLND
90  2012 Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. BMI, RPLND
91  2012 Bone marrow metastases in a patient with primary mediastinal non-seminomatous germ cell tumor - an unusual pattern of relapse. ---
92  2012 Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. ERP, PC-RPLND, RP
93  2012 Extraperitoneal laparoscopic retroperitoneal lymph node dissection for early-stage testicular nonseminomatous germ cell tumors: initial experience. EL-RLND
94  2012 High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). HDCT, SWENOTECA
95  2012 Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. PC-RPLND, RPLND
96  2012 Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy. AS, ECA, nsRPLND
97  2012 Marital status independently predicts testis cancer survival--an analysis of the SEER database. RPLND
98  2012 Post-chemotherapy robotic retroperitoneal lymph node dissection (RRPLND) in testicular cancer. PC, R-RPLND, RRPLND
99  2012 Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment. TGCT
100  2012 Retroperitoneal lymph node dissection with concomitant IVC thrombectomy, caval wall resection, and grafting for metastatic NSGCT. IVC, RPLND